For the fourth year in a row, Mayo Laboratory Inquiry has been named a Center of Excellence by BenchmarkPortal, a global leader in the contact center industry.
Herceptin has been touted as a wonder drug for women with HER2-positive breast cancer, an aggressive form of the disease that is fueled by excess production of the HER2 protein. However, not all of these patients respond to the drug, and many who do respond eventually acquire resistance. A team of researchers led by Mayo Clinic has found a promising way to circumvent this obstacle.
Mayo Clinic’s launch of eight new next-generation sequencing (NGS) panels is intended to improve the lives of patients and families living with inherited cardiac conditions by aiding in the diagnosis and management of these complex disorders. These disorders include hypertrophic cardiomyopathy, dilated cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, Noonan syndrome, Marfan syndrome, long QT syndrome, and Brugada syndrome.
Delta Regional Medical Center (DRMC), based in Greenville, MS, has selected Mayo Medical Laboratories as its primary reference laboratory. With access to Mayo Medical Laboratories’ extensive menu of laboratory tests and clinical expertise, this partnership enables DRMC to offer advanced testing capabilities to better serve its communities.
Mayo Medical Laboratories and Mayo Clinic’s Laboratory Medicine and Pathology Graduate Medical Education Office have developed Mayo Clinic PathWays, an online learning tool for pathologists and for those who enjoy learning about medicine. Practical case studies will be posted weekly to the Mayo Medical Laboratories blog for medical professionals around the world.
Mayo Medical Laboratories is partnering with Seattle Children’s Hospital to research and develop ways to help the children’s hospitals around the country decrease costs and potential errors associated with unnecessary laboratory testing.
US Senator Amy Klobuchar will tour the Mayo Clinic Biobank and discuss the Precision Medicine Initiative with leadership from both the Mayo Clinic Center for Individualized Medicine and Mayo Medical Laboratories on Friday, Feb. 20 from 11:15 to 11:40 a.m.
GenomeDx Biosciences today announced the publication of a positive validation study for the Decipher® Prostate Cancer Classifier, a new genomic test that can direct appropriate use of radiation therapy following prostate surgery.
Leica Biosystems and Mayo Clinic’s Department of Laboratory Medicine and Pathology announced today a collaboration to develop the next generation of cytogenetics imaging software.
According to a recent Mayo Clinic-led study, most patients with triple-negative breast cancer should undergo genetic testing for mutations in known breast cancer predisposition genes, including BRCA1 and BRCA2. The findings come from the largest analysis to date of genetic mutations in this aggressive form of breast cancer.
A Mayo Clinic study has found a diagnostic test based on chromosomal rearrangements can trace the lineage of lung cancer to determine whether two separate lung cancers in the same patient are independent tumors or a tumor that has spread to another region of the lung. For patients with multiple tumors, that distinction could mean the difference between early stage cancer that may be cured by surgery and incurable late-stage disease.
Hunterdon Healthcare has selected Mayo Medical Laboratories, which will give them access to our extensive menu of laboratory tests and clinical expertise.
GenomeDx Biosciences today announced that the company has expanded its research agreement with Mayo Clinic to initiate a validation study to expand the use of the Decipher® Prostate Cancer Classifier, a genomic test capable of predicting metastatic prostate cancer, for use in prostate biopsy specimens.